Multiplexed immune checkpoint interaction profiling (QF-Pro) was used to stratify response to atezolizumab in urothelial carcinoma. Researchers analyzed pre-treatment tissue microarrays from 46 patients and reported that different checkpoint interaction states correlated with progression-free survival. The study found that higher PD-1/PD-L1 interaction states aligned with better efficacy in the male cohort, while higher CTLA-4/CD80 engagement was linked to worse response. The authors emphasized that the combined assessment—high PD-1/PD-L1 with low CTLA-4/CD80 engagement—identified the best responders. The work adds to the biomarker search at a time when combination immune regimens are increasing immune-related adverse events and demand more reliable predictive tools than current single-marker approaches.